Background: Using data from a longitudinal study of young Australians, we applied recent international standards for overweight and obesity to examine associations with blood pressure (BP) and to determine the prevalence and degree of tracking of overweight and obesity. We also aimed to examine socioeconomic status in relation to these variables.
Methods: BP, height, and weight were measured at 3-year intervals from age 9 to 18, and then at 25 years of age in a Western Australian cohort. At these stages, data were available for 1,036, 1,310, 618, 615 and 600 individuals, respectively.
Results: We found 10% of 9-year-old males to be overweight or obese, while among 12-year-olds, 13% were overweight or obese; at age 15, and still at age 18, overweight or obesity was registered in 17% of this population and it rose to 42% among the 25-year-old young men. The percentage of overweight or obese females at these stages was initially 8, then 12 (at age 12), 11 (at age 15), 14 (at age 18) and finally 32. Overweight or obesity tracked to young adult life in 16% of those overweight or obese at 9, 24% at 12, 34% at 15 and 35% at 18 years. Systolic BP was significantly higher in the overweight or obese except in 12-year-olds. At the age of 25 years, 53% of men had high normal BP or were hypertensive.
Conclusions: Increasing overweight or obesity in young Australians, consistent with international trends, has serious health implications. Overweight and obesity show tracking and are predictors of higher blood pressure, except in early adolescence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ypmed.2003.09.023 | DOI Listing |
Curr Cardiol Rep
January 2025
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Purpose Of Review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, characterized by hepatic steatosis with at least one cardiometabolic risk factor. Patients with MASLD are at increased risk for the occurrence of cardiovascular events. Within this review article, we aimed to provide an update on the pathophysiology of MASLD, its interplay with cardiovascular disease, and current treatment strategies.
View Article and Find Full Text PDFAdv Ther
January 2025
Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge-IDIBELL, C/de la Feixa Llarga S/N, 08907, Hospitalet de Llobregat, Barcelona, Spain.
Introduction: Obesity and its complications are associated with high morbidity/mortality and a significant healthcare cost burden in Spain. It is therefore essential to know the potential clinical and economic benefits of reducing obesity. The objective of this study is to predict the decrease in rates of onset of potential complications associated with obesity and the cost savings after a weight loss of 15% over 10 years in Spain.
View Article and Find Full Text PDFAm J Health Promot
January 2025
Institute for Behavioral and Community Health, San Diego State University, San Diego, CA, USA.
Purpose: Social support, particularly from family, is crucial for physical activity (PA) among youth. This study examined the association between father support and moderate-to-vigorous physical activity (MVPA) in Latina pre-teens and explored the moderating role of body mass index (BMI).
Design: Cross-sectional analysis.
Aliment Pharmacol Ther
January 2025
MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
Background: The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical and lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity and specificity.
Aims: To assess the diagnostic accuracy of PEth for differentiating metabolic dysfunction and alcohol-associated liver disease (MetALD) from metabolic dysfunction-associated steatotic liver disease (MASLD) in a large, population-based, prospective, multiethnic cohort of individuals with overweight or obesity.
BMC Res Notes
January 2025
Non-Communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: Thyroid cancer is one of the most common cancers of the endocrine system. The incidence of this cancer has increased in many countries. Many cases of thyroid cancer do not have any symptoms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!